ATE440863T1 - Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion - Google Patents

Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion

Info

Publication number
ATE440863T1
ATE440863T1 AT98946057T AT98946057T ATE440863T1 AT E440863 T1 ATE440863 T1 AT E440863T1 AT 98946057 T AT98946057 T AT 98946057T AT 98946057 T AT98946057 T AT 98946057T AT E440863 T1 ATE440863 T1 AT E440863T1
Authority
AT
Austria
Prior art keywords
variants
derivatives
chemokine
analogues
inhibiting
Prior art date
Application number
AT98946057T
Other languages
English (en)
Inventor
David Grainger
Lauren Tatalick
Suzanne Kanaly
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Application granted granted Critical
Publication of ATE440863T1 publication Critical patent/ATE440863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98946057T 1997-09-11 1998-09-11 Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion ATE440863T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/927,939 US6989435B2 (en) 1997-09-11 1997-09-11 Compounds and methods to inhibit or augment an inflammatory response
PCT/US1998/019052 WO1999012968A2 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response

Publications (1)

Publication Number Publication Date
ATE440863T1 true ATE440863T1 (de) 2009-09-15

Family

ID=25455479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946057T ATE440863T1 (de) 1997-09-11 1998-09-11 Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion

Country Status (9)

Country Link
US (2) US6989435B2 (de)
EP (1) EP1012187B1 (de)
JP (1) JP4523151B2 (de)
AT (1) ATE440863T1 (de)
AU (1) AU9315398A (de)
CA (1) CA2303422A1 (de)
DE (1) DE69841105D1 (de)
ES (1) ES2332616T3 (de)
WO (1) WO1999012968A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7208152B2 (en) 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2460321A1 (en) * 2001-09-20 2003-03-27 Schering Corporation Chemokines as adjuvants of immune response
NZ553470A (en) * 2002-03-15 2008-10-31 Schering Corp Methods of modulating CD200 receptors
DK1691814T3 (da) 2003-12-01 2012-10-29 Cambridge Entpr Ltd Antiinflammatoriske midler
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
CA2596706A1 (en) * 2005-01-04 2006-07-13 University Of Rochester Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease
US20060247760A1 (en) 2005-04-29 2006-11-02 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysms adjacent branch arteries
WO2006126188A2 (en) * 2005-05-25 2006-11-30 Hadasit Medical Research Services And Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
US20110038885A1 (en) * 2007-07-26 2011-02-17 Zheng Xin Dong Chemokine analogs
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
ES2342810B1 (es) 2008-09-10 2011-07-05 Pere Poch Marti Abrebocas perfeccionado para la introduccion de mascarillas laringeasy otros dispositivos medicos a traves de la cavidad oral.
WO2010082177A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
FR2941232B1 (fr) 2009-01-16 2014-08-08 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
FR2941231B1 (fr) 2009-01-16 2016-04-01 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
EP2688913A4 (de) * 2011-03-24 2014-09-17 Univ California Hochleistungsproduktion rekombinanter proteine
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP6403062B2 (ja) 2012-12-21 2018-10-10 国立大学法人徳島大学 組織修復活性組成物及びその利用
ITRM20130199A1 (it) 2013-04-03 2014-10-04 Irbm Science Park S P A Peptidi per uso dermatologico e/o cosmetico
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
EP3731850A4 (de) * 2017-12-29 2021-12-01 Oncorus, Inc. Onkolytische virale verabreichung von therapeutischen polypeptiden
US20240139376A1 (en) * 2021-02-12 2024-05-02 Rhode Island Hospital Reconstitution of extracellular matrixes for musculoskeletal joint tissue repair using biomimetic biologic and synthetic factors

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740788A (en) * 1956-04-03 J-hydroxy-n-propargyl-morphinanes
US2726243A (en) * 1954-01-08 1955-12-06 Ciba Pharm Prod Inc Hydrazides of yohimbic acid
US2743270A (en) * 1954-05-26 1956-04-24 Univ Michigan Heterocyclic nitrogen compounds
FR2135087B1 (de) 1971-05-06 1974-08-23 Serdex
FR2229403B2 (de) 1973-05-18 1976-08-13 Serdex Etud Rech Diffusion Ex
FR2239471A1 (en) 1973-08-03 1975-02-28 Omnium Chimique Sa Corynanthine hydrazides - as therapeutic agents
HU172479B (hu) 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Sposob poluchenija novykh soedinenij s ehrgolenovymi i
US4737580A (en) 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US5248666A (en) 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
EP0215805A1 (de) 1985-01-18 1987-04-01 MERCK PATENT GmbH Immunoregulatorische peptide
JPS62501502A (ja) * 1985-01-18 1987-06-18 イミユーンテツク・フアーマシユーテイカルズ 免疫調節性ペプチド
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4774318A (en) 1985-11-22 1988-09-27 Oncogen Snake venom growth arresting peptide
WO1988006628A1 (en) 1987-03-02 1988-09-07 Bristol-Myers Company Platelet related growth regulator
US5827821A (en) 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5202118A (en) 1987-12-18 1993-04-13 Immunex Corporation Method for promoting wound healing using IL-1
DE68925032T2 (de) 1988-08-15 1996-04-25 Brigham & Womens Hospital Leukozyten-adhäsions-inhibitor.
IL92938A (en) 1989-01-01 1998-08-16 Us Commerce A polypeptide that has a mutagenic activity on monocytes and AND that encodes it
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
US5484885A (en) 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
AU6747190A (en) 1989-11-29 1991-06-26 Brigham And Women's Hospital Endothelial-derived il-8
US5661132A (en) 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5079228A (en) 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5190918A (en) 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5155038A (en) 1990-02-22 1992-10-13 W. R. Grace & Co.-Conn. Use of thrombospondin to promote wound healing
US5190920A (en) 1990-09-24 1993-03-02 W. R. Grace & Co.-Conn. Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity
CA2041271A1 (en) 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5824647A (en) 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
EP0592529A4 (de) 1991-06-21 1994-12-14 Univ Temple Calpain hemmende peptidanaloga der schweren kette der kininogens.
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5707814A (en) 1991-11-01 1998-01-13 The Regents Of The University Of California CD8+ cell antiviral factor
US5326752A (en) 1991-11-27 1994-07-05 Glycomed Incorporated Substituted lactose and lactosamine derivatives as cell adhesion inhibitors
ATE169638T1 (de) 1991-12-04 1998-08-15 Biomedical Res Centre Ltd Analoge des menschlichen interleukin-8.
US5357041A (en) 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
JPH0625288A (ja) 1992-07-10 1994-02-01 Kuraray Co Ltd ペプチドまたはその塩
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
WO1994009128A1 (en) 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
WO1994020512A2 (en) 1993-03-01 1994-09-15 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
US5627265A (en) 1993-03-05 1997-05-06 Washington University Receptor for cell-binding domain of thrombospondins
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
JP3623985B2 (ja) 1993-05-31 2005-02-23 財団法人化学及血清療法研究所 抗ｌｄ７８ポリペプチドモノクローン抗体
DE69434593D1 (de) 1993-08-13 2006-02-02 Uab Res Foundation Birmingham Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta
JPH0782169A (ja) 1993-09-13 1995-03-28 Toray Ind Inc 創傷治療剤
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
US5578714A (en) 1993-10-21 1996-11-26 New York Blood Center, Inc. DNA encoding Duffy 9pd protein
US5459128A (en) 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1995017421A1 (en) 1993-12-22 1995-06-29 Temple University - Of The Commonwealth System Of Higher Education PEPTIDE ANALOGS OF THE FACTOR IXa PLATELET BINDING SITE
WO1995017420A1 (en) 1993-12-22 1995-06-29 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the activated platelet binding site on factor xi
US6132987A (en) 1994-01-13 2000-10-17 The Regents Of The University Of California Recombinant mammalian monocyte chemotactic protein-1 (MCP-1) receptors (MCP-1R, CCR-2)
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
GB9406463D0 (en) 1994-03-31 1994-05-25 Medical Res Council Cervical ripening
US5627156A (en) 1994-09-23 1997-05-06 University Of Nebraska Board Of Regents Polypeptide agonists for human interleukin-8
US5877276A (en) 1994-09-23 1999-03-02 The Board Of Regents Of The University Of Nebraska Polypeptide agonists for human interleukin-8
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
WO1996020722A1 (en) 1995-01-03 1996-07-11 Thomas Jefferson University Compounds that inhibit t cell proliferation and methods using the same
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
JPH11503110A (ja) 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
US5955485A (en) 1995-02-23 1999-09-21 Janssen Pharmaceutica, N.V. Use of fused benzothiazoles as neuroprotectants
WO1996029074A1 (en) 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception
US5817911A (en) 1995-04-07 1998-10-06 Regents Of The University Of California Transgenic mice expressing alveolar MCP-1
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
AU6406496A (en) 1995-06-29 1997-01-30 Thomas Jefferson University Cd4-derived peptides that inhibit immune responses
GB9518611D0 (en) 1995-09-12 1995-11-15 Ludwig Inst Cancer Res Anti-apoptotic factors
ES2233978T3 (es) 1995-09-27 2005-06-16 SHIONOGI & CO., LTD. Proteina analoga a la quimiocina de tipo cc.
EP0862449A4 (de) 1995-09-29 1998-11-11 Immunex Corp Chemokin-inhibitor
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997019173A1 (en) 1995-11-21 1997-05-29 Smithkline Beecham Corporation Method of treating sepsis
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
AU1532697A (en) 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
WO1997029192A1 (en) 1996-02-12 1997-08-14 Schering Corporation Mammalian dendritic cell chemokine reagents
WO1997031098A1 (en) 1996-02-23 1997-08-28 Human Genome Sciences, Inc. Human chemokine polypeptides
DE69731373T2 (de) 1996-03-01 2006-03-09 Euroscreen S.A. Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
JPH09255570A (ja) 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
EP1021181A4 (de) 1996-03-28 2002-06-26 Smithkline Beecham Corp Indolcarbonsäuren als chemokin-inhibitoren
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
GB2319252A (en) 1996-11-08 1998-05-20 Diapharm Limited Polypeptides involved in the interaction of HIV gp120 with the fusin, and the CC-CKR-5 co-receptors thereof
US5700821A (en) 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
US6274342B1 (en) 1996-09-18 2001-08-14 Center For Blood Research, Inc. Nucleic acid molecules encoding monocyte chemotactic protein 5 (MCP-5) molecules and uses therefor
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
JP3614610B2 (ja) 1997-05-02 2005-01-26 新日鉄ソリューションズ株式会社 メール送信システム、メール送信方法及び記録媒体
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP0906954A1 (de) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
AU4835599A (en) 1998-06-29 2000-01-17 Edwin F. Ullman Assay for homocysteine
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
CA2383559A1 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium

Also Published As

Publication number Publication date
AU9315398A (en) 1999-03-29
EP1012187A2 (de) 2000-06-28
US20060073114A1 (en) 2006-04-06
US20010006640A1 (en) 2001-07-05
US6989435B2 (en) 2006-01-24
JP2001515918A (ja) 2001-09-25
JP4523151B2 (ja) 2010-08-11
ES2332616T3 (es) 2010-02-09
CA2303422A1 (en) 1999-03-18
WO1999012968A3 (en) 1999-07-29
US7700087B2 (en) 2010-04-20
WO1999012968A2 (en) 1999-03-18
EP1012187B1 (de) 2009-08-26
DE69841105D1 (de) 2009-10-08

Similar Documents

Publication Publication Date Title
ATE440863T1 (de) Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion
CA2236166A1 (en) Enhancer-increased gene expression in plants
NZ333128A (en) Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
HU9601448D0 (en) Novel apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof
DE69312232D1 (de) Bpc-peptide, ihre herstellung und verwendung
BR9811592A (pt) Oxidase de citocinina
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
BR0312889A (pt) Polipeptìdeo t20 peguilado
NO964022L (no) -2-antichymotrypsinanaloger med elastasehemmende aktivitet
ATE192490T1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
DK0544826T3 (da) Overlegne trombomodulinanaloger til farmaceutisk anvendelse
ATE517912T1 (de) Protein, das an der wiederherstellung der fruchtbarkeit nach cytoplasmischer männlicher sterilität beteiligt ist, und ein dieses codierendes gen
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
DE60104702D1 (de) Auftrennung von isomeren von n-[n-(3,3-dimethylbutyl)-l- alpha-aspartyl]-l-phenylalanin-1-methylester durch verwendung mittels metallischer ionen
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ES2127516T3 (es) Peptidos para inhibir la liberacion de pepsina.
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties